The EU-PEARL project aims to shape future drug development through a systematic approach that enables patient focused, cross company collaborative platform trials
- The EU Patient-cEntric clinicAl tRial pLatforms (EU-PEARL) is a unique public-private strategic partnership focused on creating a framework to set up adaptive clinical trial platforms of the future
- EU-PEARL hopes to transform clinical trials into a cross-company collaborative, multi-compound platform focused on patients
- EU-PEARL aims to define a novel enabling infrastructure where pharmaceutical companies and healthcare providers can work together and integrated research platforms will become an obtainable alternative
For the first time, 36 world-leading institutions among European university hospitals, research centers, patient groups, non-profit product developers and pharmaceutical companies are coming together to shape the adaptive clinical trial platform of the future. The project, called EU Patient-cEntric clinicAl tRial pLatforms (EU-PEARL), is a unique public-private strategic partnership funded by the Innovative Medicines Initiative (IMI) to conceptualize and lead the design of an integrated research platform, enabling patient-centric drug development in Europe.
Participants in EU-PEARL have the ambition of transforming the current approach of conducting single-compound clinical trials into the use of cross-company Integrated Research Platforms (IRPs), specifically for early development and focused on patients’ interests, while seeking opportunities to address medical needs through the advancement of novel molecules.
The EU-PEARL initiative intends to develop new methods, tools and frameworks to create a novel enabling infrastructure for conducting patient-centric platform trials through an integrated system where pharmaceutical companies, non-profit product developers and healthcare providers work together. The intent is to shape future clinical trials that will be more patient friendly by design and patient focused by outcome in four diseases areas: Major Depressive Disorder, Tuberculosis, Non-Alcoholic Steatohepatitis and Neurofibromatosis; and provide the framework for designing and executing IRPs in other disease areas.
Read the full press-release:Download PDF